 |
| Medical Cannabis – Wikimedia Commons Image |
Paul Armentano, Deputy Director
NORML
The long-term administration of delta-9-THC, the primary psychoactive compound in marijuana, is associated with decreased mortality in monkeys infected with the simian immunodeficiency virus (SIV), a primate model of HIV (human immunodeficiency virus) disease, according to in vivo experimental trial data published in the June issue of the journal AIDS Research and Human Retroviruses.
Investigators at the Louisiana State University Health Sciences Center assessed the impact of chronic intramuscular THC administration compared to placebo on immune and metabolic indicators of SIV disease during the initial six-month phase of infection.
Researchers reported, “Contrary to what we expected, … delta-9-THC treatment clearly did not increase disease progression, and indeed resulted in generalized attenuation of classic markers of SIV disease.” Authors also reported that THC administration was associated with “decreased early mortality from SIV infection” and “retention of body mass.”
Investigators concluded, “These results indicate that chronic delta-9-THC does not increase viral load or aggravate morbidity and may actually ameliorate SIV disease progression.”
Clinical trials have previously documented that the short-term inhalation of cannabis does not adversely impact viral loads in HIV patients, and may even improve immune function.
Additional studies documenting the disease modifying potential of marijuana is available in the NORML handbook, Emerging Clinical Applications For Cannabis & Cannabinoids: Fourth Edition, available online here.
Additional information on this suit will appear in this week’s NORML news update. To receive these e-mail updates free, please sign up here.
linkwithin_text=’Related Articles:’
Be the first to comment on "Cannabinoid Administration Halts Disease Progression, Decreases Mortality In Primate Version of Human Immunodeficiency Virus (HIV)"